Drug Trial Radar · NCT01228357
Predict Antidepressant Responsiveness Using Pharmacogenomics
Last checked: Nov 19, 2026Latest source record: Dec 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Feb 2003
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Samsung Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 26, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years, up to 89 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether genetic information associated with individual depressive symptoms.
Conditions
- Depression
- Depressive Symptoms
Interventions
SSRI treated groupDrug
Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
non-SSRI treated groupDrug
Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presences of each individual symptom of depression at 1,2,4,6,12 weeksTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Kangnam, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.